Have a personal or library account? Click to login
Immunohistochemical Expression of Epidermal Growth Factor Receptor in Hepatocellular Carcinoma Cover

Immunohistochemical Expression of Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Open Access
|Dec 2018

References

  1. 1. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74–108.10.3322/canjclin.55.2.7415761078
  2. 2. Hashem B. El-Serag. Hepatocellular Carcinoma. N Engl J Med 2011; 365: 1118–1127 DOI: 10.1056/NEJMra100168310.1056/NEJMra100168321992124
  3. 3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.10.1053/j.gastro.2007.04.06117570226
  4. 4. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World Journal of Gastroenterology : WJG. 2008; 14(27):4 300–4308. doi:10.3748/wjg.14.4300.10.3748/wjg.14.4300273118018666317
  5. 5. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From Cirrhosis to Hepatocellular Carcinoma: New Molecular In sights on Inflammation and Cellular Senescence. Liver Cancer. 2013; 2(3–4): 367–383. doi:10.1159/000343852.10.1159/000343852388131924400224
  6. 6. Gilgenkrantz H, de l’Hortet AC. New insights into liver regeneration. Clin Res Hepatol Gastroenterol. 2011; 35: 623–9. DOI:10.1016/j.clinre.2011.04.002.10.1016/j.clinre.2011.04.00221613004
  7. 7. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. J Hepatol. 2012; 57: 692–4. DOI:10.1002/hep.20969.10.1002/hep.2096916447274
  8. 8. Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol. 2014 Jan; 49(1): 9-23. doi: 10.1007/s00535-013-0907-x.10.1007/s00535-013-0907-x24318021
  9. 9. Gea VH, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013; 144(3): 512–27.10.1053/j.gastro.2013.01.002357806823313965
  10. 10. Nikolaou K, Sarris M, Talianidis I. Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer. Clin Cancer Res. 2013; 1(19): 2810–6.10.1158/1078-0432.CCR-12-196123549874
  11. 11. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013; 2013: 187204.10.1155/2013/187204359118023533994
  12. 12. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012; 56: 769–75.10.1002/hep.25670408715922378017
  13. 13. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006 Jan 17; 366(1): 2–16.10.1016/j.gene.2005.10.01816377102
  14. 14. Hirsh FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene2009; 28: S32–S37. Doi:10.1038/onc.2009.199.10.1038/onc.2009.19919680294
  15. 15. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein over-expression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006 Mar 1; 118(5): 1173–80.10.1002/ijc.2145416161046
  16. 16. Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver. 1997; 17: 177–82. PMID: 929848710.1111/j.1600-0676.1997.tb00803.x9298487
  17. 17. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;26(25): 3787–800. DOI: 10.1038/sj.onc.120955610.1038/sj.onc.120955616799620
  18. 18. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193–199. PMID:11925590.10.3748/wjg.v8.i2.193465834911925590
  19. 19. Zhu AX, Rosmorduc O, Evans J.T.R., Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: A Phase III, Randomized, Double-Blind,Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. J Clin Oncol 2015; 33: 559–566.10.1200/JCO.2013.53.774625547503
  20. 20. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti K3, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 January; 16(1): 15–31. doi:10.1517/14728222.2011.648617.10.1517/14728222.2011.648617329178722239438
  21. 21. Wu X and Li Y. Signaling Pathways in Liver Cancer, in Alexander Julianov. Liver Tumors. IntechOpen, February 3rd 2012. DOI: 10.5772/31381. Available from: https://www.intechopen.com/books/liver-tumors/signaling-pathways-in-liver-cancer.10.5772/31381.Availablefrom:https://www.intechopen.com/books/liver-tumors/signaling-pathways---
  22. 22. Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, et al. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel). 2011 May 18; 3(2): 2444–61. doi: 10.3390/cancers3022444.10.3390/cancers3022444
  23. 23. Jorissen R.N, Walker F, Pouliot, N, Garrett T.P, Ward C.W, Burgess A.W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 2003; 284, 31–53.10.1016/S0014-4827(02)00098-8
  24. 24. Citri A, Yarden Y. EGF-ErbB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006; 7, 505–516.10.1038/nrm1962
  25. 25. Schneider M.R, Wolf E. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol. 2009; 218, 460–466.10.1002/jcp.21635
  26. 26. Komposch K, Sibilia M. EGFR Signaling in Liver Diseases. Int J Mol Sci. 2015 Dec 29; 17(1). pii: E30. doi: 10.3390/ijms17010030.10.3390/ijms17010030
  27. 27. Carver RS, Stevenson MC, Scheving LA, Russell WE. Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Gastroenterology. 2002; 123: 2017–27.10.1053/gast.2002.37060
  28. 28. Berasain C, Perugorrıa MJ, Latasa MU, Castillo J, Goni S, Santamaría M, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood). 2009; 234: 713–25.10.3181/0901-MR-12
  29. 29. Komuves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000 Jun; 48(6): 821–30. DOI:10.1177/002215540004800610.10.1177/002215540004800610
  30. 30. Qiao Q, Zhang J, Wang W, Li Q. Over expression of transforming growth factor-alpha and epidermal growth factor receptor in human hepatic cirrhosis tissues. Hepatogastroenterology. 2008 Jan-Feb; 55(81): 169–72. PMID:18507100.
  31. 31. Mantovani A, Allavena P, Sica A, BalkwillF. Cancer-related inflammation. Nature 2008; 454: 436–444 doi:10.1038/nature07205.10.1038/07205
  32. 32. Uslu S, Kirimlioglu H, Ince U. Analysis of Epidermal Growth Factor Receptor Expression in Hepatocellular Carcinoma: A Comparision of Fluorescence in Situ Hybridization and Immunochemistry. J Gastroenterol Hepatol Res 2014; 3(8): 1193–1197 URL: http://www.ghrnet.org/index.php/joghr/article/view/815.
  33. 33. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K et al. Expression and clinical significance of ErbB receptor family in hepatocellular carcinoma. Br. J. Cancer 2001; 84, 1377–1383. DOI:10.1054/bjoc.2000.1580.10.1054/bjoc.2000.1580
  34. 34. Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, et al. Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol. Carcinogenes. 2003; 36, 130–141. doi.org/10.1002/mc.10103.10.1002/mc.10103
  35. 35. DeCicco LA, Kong J, Ringer DP.Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat. Cancer Lett. 1997 Jan 1; 111(1–2): 149–56.10.1016/S0304-3835(96)04524-7
  36. 36. Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues. BioMed Research International,Volume 2015, Article ID 171845, 7 pages http://dx.doi.org/10.1155/2015/17184510.1155/2015/171845457598526436086
  37. 37. Ali R, Wendt MK. The paradoxa functions of EGFR during breast cancer progression. Signal Transduction and Targeted Therapy, volume 2 Article number: 16042 (2017) doi:10.1038/sigtrans.2016.42.10.1038/sigtrans.2016.42539711928435746
  38. 38. Whittaker S, Marais R, Zhu AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010 Sep 9; 29(36): 4989–5005. doi: 10.1038/onc.2010.236. Epub 2010 Jul 19.10.1038/onc.2010.236.Epub2010Jul19
  39. 39. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK.Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan; 16(1): 15–31. doi: 10.1517/14728222.2011.648617. Epub 2012 Jan 12.10.1517/14728222.2011.648617.Epub201212
  40. 40. Eggert T, Greten TF. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion. 2017; 96(1): 1-4. doi: 10.1159/000464282. Epub 2017 Jun 13.2860574510.1159/000464282.Epub201713
DOI: https://doi.org/10.2478/prilozi-2018-0038 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Language: English
Page range: 21 - 28
Published on: Dec 31, 2018
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2018 Dafina Nikolova, Viktorija Chalovska, Magdalena Genadieva Ivanova, Emilija Nikolovska, Ance Volkanovska, Nikola Orovchanec, Slavica Kostadinova Kunovska, Gordana Petrushevska, Vesna Janevska, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.